Stock listing
NASDAQ:ALGS Aligos Therapeutics, Inc. Stock
Home listing (NASDAQ) of Aligos Therapeutics, Inc.
Follow Aligos Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ALGS
$1.22 USD -0.08 (-6.2%)
Close on Nov 20, 2026
- Day range
- $1.18 – $1.34 USDNov 20, 2026
- Volume
- 105,409 sharesNov 20, 2026
- Market cap
- $6.64M USDAt the close on Nov 20, 2026 · price × 5.44M shares outstanding
- 52-week range
- $1.18 – $13.69 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $254,362 USDMedian day 42,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALGS · Home | $1.22 USD | -0.08 (-6.2%) | 105,409 | $1.26 | $1.336 | $1.175 | $1.30 | Close on Nov 20, 2026 |
| Frankfurt:5WK0 | €1.138 EUR | -0.044 (-3.7%) | 190 | €1.106 | €1.138 | €1.106 | €1.182 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALGS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.22 | -0.08 | -6.2% | $1.26 | $1.336 | $1.175 | 105,409 | |
| $1.30 | -0.06 | -4.4% | $1.39 | $1.58 | $1.25 | 109,147 | |
| $1.36 | -0.30 | -18.1% | $1.63 | $1.63 | $1.36 | 57,117 | |
| $1.66 | -0.44 | -21.0% | $2.00 | $2.00 | $1.58 | 139,603 | |
| $2.10 | +0.12 | +6.1% | $2.09 | $2.245 | $1.98 | 57,515 | |
| $1.98 | -0.18 | -8.3% | $2.21 | $2.316 | $1.92 | 120,576 | |
| $2.16 | -0.41 | -16.0% | $2.79 | $2.81 | $2.02 | 283,400 | |
| $2.57 | -1.38 | -34.9% | $3.99 | $3.99 | $2.56 | 194,200 | |
| $3.95 | -0.12 | -2.9% | $4.25 | $4.65 | $3.95 | 141,300 | |
| $4.07 | -0.44 | -9.8% | $4.44 | $4.855 | $4.00 | 101,700 | |
| $4.51 | -0.51 | -10.2% | $5.004 | $5.004 | $4.505 | 40,200 | |
| $5.02 | +0.27 | +5.7% | $4.89 | $5.14 | $4.721 | 27,800 | |
| $4.75 | +0.15 | +3.3% | $4.65 | $4.95 | $4.65 | 13,900 | |
| $4.60 | -0.20 | -4.2% | $4.81 | $4.99 | $4.60 | 23,000 | |
| $4.80 | -0.23 | -4.6% | $4.99 | $5.05 | $4.75 | 23,800 | |
| $5.03 | -0.14 | -2.7% | $5.02 | $5.375 | $5.02 | 47,200 | |
| $5.17 | +0.43 | +9.1% | $4.66 | $5.26 | $4.66 | 23,500 | |
| $4.74 | +0.09 | +1.9% | $4.67 | $4.81 | $4.63 | 9,500 | |
| $4.65 | -0.13 | -2.7% | $4.98 | $4.98 | $4.55 | 33,000 | |
| $4.78 | -0.04 | -0.8% | $4.76 | $4.92 | $4.65 | 4,800 | |
| $4.82 | -0.14 | -2.8% | $5.005 | $5.005 | $4.78 | 15,300 | |
| $4.96 | -0.07 | -1.4% | $4.88 | $5.235 | $4.88 | 13,100 | |
| $5.03 | +0.19 | +3.9% | $4.74 | $5.241 | $4.74 | 42,800 | |
| $4.84 | -0.02 | -0.4% | $4.95 | $5.08 | $4.61 | 82,000 | |
| $4.86 | -0.53 | -9.8% | $5.32 | $5.50 | $4.86 | 67,600 | |
| $5.39 | +0.16 | +3.1% | $5.40 | $5.409 | $5.186 | 25,500 | |
| $5.23 | -0.28 | -5.1% | $5.50 | $5.60 | $5.21 | 60,600 | |
| $5.51 | -0.02 | -0.4% | $5.465 | $5.60 | $5.20 | 34,000 | |
| $5.53 | +0.19 | +3.6% | $5.50 | $5.64 | $5.30 | 57,300 | |
| $5.34 | +0.03 | +0.6% | $5.27 | $5.442 | $5.27 | 8,900 | |
| $5.31 | -0.01 | -0.2% | $5.25 | $5.53 | $5.08 | 37,400 | |
| $5.32 | -0.06 | -1.1% | $5.33 | $5.525 | $5.23 | 19,400 | |
| $5.38 | -0.02 | -0.4% | $5.46 | $5.53 | $5.31 | 12,800 | |
| $5.40 | -0.14 | -2.5% | $5.57 | $5.65 | $5.35 | 48,600 | |
| $5.54 | +0.04 | +0.7% | $5.58 | $5.72 | $5.37 | 29,000 | |
| $5.50 | -0.13 | -2.3% | $5.69 | $5.74 | $5.367 | 28,300 | |
| $5.63 | +0.01 | +0.2% | $5.65 | $5.80 | $5.54 | 35,300 | |
| $5.62 | +0.08 | +1.4% | $5.53 | $5.68 | $5.40 | 11,500 | |
| $5.54 | +0.03 | +0.5% | $5.38 | $5.54 | $5.18 | 79,500 | |
| $5.51 | -0.04 | -0.7% | $5.70 | $5.765 | $5.47 | 45,000 | |
| $5.55 | -0.01 | -0.2% | $5.55 | $5.695 | $5.27 | 59,600 | |
| $5.56 | -0.12 | -2.1% | $5.72 | $5.936 | $5.45 | 35,100 | |
| $5.68 | +0.19 | +3.5% | $5.57 | $6.30 | $5.222 | 75,700 | |
| $5.49 | +0.25 | +4.8% | $5.31 | $5.88 | $5.21 | 125,000 | |
| $5.24 | +0.07 | +1.4% | $5.15 | $5.25 | $5.015 | 21,300 | |
| $5.17 | +0.12 | +2.4% | $5.10 | $5.29 | $5.10 | 21,700 | |
| $5.05 | +0.06 | +1.2% | $5.01 | $5.13 | $4.93 | 41,700 | |
| $4.99 | -0.05 | -1.0% | $5.04 | $5.445 | $4.82 | 34,100 | |
| $5.04 | -0.18 | -3.4% | $5.17 | $5.27 | $5.02 | 28,000 | |
| $5.22 | -0.11 | -2.1% | $5.39 | $5.502 | $5.14 | 37,000 | |
| $5.33 | -0.17 | -3.1% | $5.38 | $5.48 | $5.21 | 46,100 | |
| $5.50 | -0.26 | -4.5% | $5.79 | $6.02 | $5.41 | 33,000 | |
| $5.76 | -0.45 | -7.2% | $6.21 | $6.34 | $5.62 | 63,600 | |
| $6.21 | -0.01 | -0.2% | $6.16 | $6.21 | $6.02 | 20,300 | |
| $6.22 | +0.01 | +0.2% | $6.22 | $6.48 | $6.07 | 42,100 | |
| $6.21 | +0.12 | +2.0% | $6.15 | $6.64 | $6.01 | 55,200 | |
| $6.09 | +0.23 | +3.9% | $5.76 | $6.22 | $5.61 | 101,600 | |
| $5.86 | -1.05 | -15.2% | $6.83 | $6.83 | $5.86 | 98,700 | |
| $6.91 | -0.16 | -2.3% | $7.025 | $7.10 | $6.64 | 39,100 | |
| $7.07 | -0.44 | -5.9% | $7.44 | $7.495 | $6.82 | 80,300 | |
| $7.51 | +0.04 | +0.5% | $7.37 | $7.72 | $7.04 | 68,900 | |
| $7.47 | +0.54 | +7.8% | $6.93 | $7.538 | $6.71 | 93,400 | |
| $6.93 | +0.26 | +3.9% | $6.61 | $7.00 | $6.40 | 33,200 | |
| $6.67 | +0.23 | +3.6% | $6.48 | $6.799 | $6.40 | 52,300 | |
| $6.44 | -0.45 | -6.5% | $6.77 | $7.006 | $6.35 | 62,500 |
Splits
1 split · NASDAQ:ALGS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation |
- Ticker
- NASDAQ:ALGS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 6, 2026
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Latest news
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Nov 6, 2026
Closed $4.07 (-9.8%) on Nov 6, 2026
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
Nov 5, 2026
Closed $4.07 (-9.8%) on Nov 6, 2026
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
Oct 5, 2026
Closed $5.38 (-0.4%) on Oct 6, 2026
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
Sep 2, 2026
Closed $6.21 (+2.0%) on Sep 2, 2026
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
Aug 12, 2026
Closed $6.77 (-3.3%) on Aug 13, 2026
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
Jul 30, 2026
Closed $4.32 (+1.6%) on Jul 30, 2026
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
Jul 13, 2026
Closed $6.36 (-3.9%) on Jul 13, 2026
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Jul 6, 2026
Closed $6.09 (+4.1%) on Jul 7, 2026
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
May 27, 2026
Closed $5.60 (-2.4%) on May 27, 2026
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
May 13, 2026
Closed $6.67 (+3.1%) on May 13, 2026
Aligos Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 135 in all · newest Nov 6, 2026 · oldest 2020
- Decks
- 34 decks · latest March 2025
Where Aligos Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALGS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ALGS | BOATS | United States | USD |
| gettex:5WK0 | gettex | Germany | EUR |
| LS Exchange:A40LQ4 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A40LQ4 | Lang & Schwarz | Germany | EUR |
| Tradegate:5WK0 | Tradegate | Germany | EUR |
| Dusseldorf:5WK0 | Dusseldorf | Germany | EUR |
| Frankfurt:5WK0 | Frankfurt | Germany | EUR |
| Munich:5WK0 | Munich | Germany | EUR |
| Stuttgart:5WK0 | Stuttgart | Germany | EUR |
Valuation
EV/sales −2.1× against a median of 2.8×: 2nd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$12.55M USD
- P/E
- Loss
- EV/sales
- −2.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 1.1×
- Beta vs S&P 500
- 1.63
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. · NASDAQ:ALGS | US$6.64M | −US$12.55M | n/a | −2.1× | n/a | 0.6× | n/a | 1.1× | 1.63 |
| Arctic Bioscience AS · OSL:ABS | US$7.00M | US$11.38M | n/a | 2.8× | n/a | 0.4× | −102.3% | 0.3× | n/a |
| Alaunos Therapeutics, Inc. · NASDAQ:TCRT | US$6.99M | US$6.37M | n/a | 2,124× | n/a | 7.2× | n/a | 0.0× | 0.90 |
| Curanex Pharmaceuticals Inc · NASDAQ:CURX | US$6.92M | US$5.88M | n/a | n/a | n/a | 2.7× | n/a | 0.2× | 0.84 |
| Cambium Bio Ltd · ASX:CMB | US$6.82M | US$6.18M | n/a | 14.6× | n/a | 4.3× | −638.4% | 0.1× | n/a |
| MetaVia Inc. · NASDAQ:MTVA | US$6.81M | −US$1.97M | n/a | n/a | n/a | 2.8× | n/a | 0.0× | 1.22 |
| ZEO ScientifiX Inc. · OTC:ZEOX | US$6.51M | US$5.27M | n/a | 1.0× | n/a | n/a | −106.2% | n/a | 0.54 |
| FibroBiologics, Inc. · NASDAQ:FBLG | US$6.34M | US$5.17M | n/a | n/a | n/a | 3.5× | n/a | 0.0× | 0.34 |
| GT Biopharma, Inc. · NASDAQ:GTBP | US$6.33M | −US$3.60M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | 1.57 |
| Kyntra Bio, Inc. · NASDAQ:KYNB | US$6.32M | −US$33.97M | n/a | −6.4× | n/a | n/a | −326.0% | n/a | 1.58 |
| Acurx Pharmaceuticals, Inc. · NASDAQ:ACXP | US$6.30M | −US$3.35M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Median of the others | US$6.66M | US$5.22M | 2.8× | 2.8× | −216.1% | 0.0× | 1.06 |
Forecasts
7 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 52.38 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.28 · 6 analysts
- Revenue, year to Dec 2026
- 33.54M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Lawrence M. Blatt | Chairman, President, & Chief Executive Officer |
| Lesley Ann Calhoun | Executive Vice President, Chief Operating Officer, and Chief Financial Officer |
| Jordyn Tarazi | Vice President, Investor Relations & Corporate Communications |
| David B. Smith | Executive Vice President, Head of Chemical Operations |
| Jim Hassard | EVP, Chief Commercial Officer |
| Julian Symons | Executive Vice President, Chief Scientific Officer |
| Kristina Engeseth | Senior Vice President, Head of People & Culture |
| Rámon Polo | Senior Vice President, Head of Global Regulatory Affairs |
| Sushmita M. Chanda | Executive Vice President, Chief Development Officer |
| Tse-I Lin | Senior Vice President, Early Compound Development, Belgian Site Head |
Board
| Director | Role |
|---|---|
| Lawrence M. Blatt | Chairman, President, & Chief Executive Officer |
| Bridget Martell | Director |
| Carole Nuechterlein | Director |
| Heather Preston | Director |
| James Scopa | Director |
| K. Peter Hirth | Director |
| Margarita Chavez | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 6, 2026 · Before open | −9.8% |
| Q2 2026 | Aug 6, 2026 · Before open | +16.2% |
| Q1 2026 | May 8, 2026 | +3.0% |
| Q4 2025 | Mar 5, 2026 · Before open | −2.9% |
| Q3 2025 | Nov 6, 2025 · Before open | −3.1% |
| Q2 2025 | Aug 6, 2025 · After close | +1.1% |
| Q1 2025 | May 6, 2025 · Before open | −9.3% |
| Q4 2024 | Mar 10, 2025 · Before open | −19.6% |
| Q3 2024 | Nov 6, 2024 · After close | +6.1% |
| Q2 2024 | Aug 6, 2024 · After close | +21.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −0.9% |
| Q4 2023 | Mar 12, 2024 · After close | 0.0% |
| Q3 2023 | Nov 2, 2023 · After close | +1.3% |
| Q2 2023 | Aug 3, 2023 · After close | −0.6% |
| Q1 2023 | May 4, 2023 · After close | −8.8% |
| Q4 2022 | Mar 9, 2023 · After close | −2.9% |
| Q3 2022 | Nov 2, 2022 · After close | −1.9% |
| Q2 2022 | Aug 4, 2022 · After close | +7.9% |
| Q1 2022 | May 4, 2022 · After close | −11.3% |
| Q4 2021 | Mar 10, 2022 · After close | +5.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| APASL 2025 | Conference | 19 slides | March 2025 |
| Technical Presentation (November 2024) | Technical | 19 slides | Nov 1, 2024 |
| Investor Presentation (October 2024) | Investor deck | 43 slides | October 2024 |
| Investor Presentation (August 2024) | Investor deck | 41 slides | August 2024 |
| Investor Presentation (June 2024) | Investor deck | 43 slides | June 2024 |
| Investor Presentation (May 2024) | Investor deck | 40 slides | May 2024 |
| Investor Presentation (April 2024) | Investor deck | 40 slides | April 2024 |
| Investor Presentation (April 2024) | Investor deck | 37 slides | April 2024 |
| Investor Presentation (March 2024) | Investor deck | 35 slides | March 2024 |
| Investor Presentation (February 2024) | Investor deck | 44 slides | February 2024 |
All 34 decks
Financings
| Raise | Date |
|---|---|
| Private placement of common stock, pre-funded warrants and accompanying warrants Announced: about US$105M · US$26.0825 a share · Warrants at US$26.02 · Jefferies +2 Dealers: Jefferies, Piper Sandler, H.C. Wainwright & Co. Use of proceeds: Advance ALG-000184 into a Phase 2 study in chronic hepatitis B and general corporate purposes | Feb 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$15.00 a share on Oct 15, 2020.
- Price
- US$15.00 a share
- Shares offered
- 10,000,000 shares of common stock
- Offering size
- US$150 million
- Underwriters' option
- Up to 1,500,000 more shares
- Underwriters
- J.P. Morgan, Jefferies, Piper Sandler, Cantor · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 26, 2020 |
| Filed publicly | Sep 25, 2020 |
| Amended once | Oct 9, 2020 |
| Shares registered with an exchange | Oct 13, 2020 |
| Declared effective by the SEC | Oct 15, 2020 |
| Final prospectus, with the price | Oct 19, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 19, 2020 |
| EFFECT · Notice that a registration is effective | Oct 15, 2020 |
| CERT · Exchange's certificate of listing | Oct 14, 2020 |
| CORRESP · Letter to the SEC | Oct 13, 2020 |
| CORRESP · Letter to the SEC | Oct 13, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 13, 2020 |
| S-1/A · Registration statement, amended | Oct 9, 2020 |
| CORRESP · Letter to the SEC | Oct 2, 2020 |
| CORRESP · Letter to the SEC | Sep 25, 2020 |
| S-1 · Registration statement | Sep 25, 2020 |
All 12 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Sep 23, 2020 |
| DRS · Draft registration statement | Aug 26, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 19, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.19M | 3.61M | 6.19M | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 930.0K | 2.62M | 3.07M | 3.67M | 104.2M | 3.33M | 2.30M | 1.29M |
| Gross profit | 1.26M | 3.94M | 15.5M | 13.9M | 4.36M | -10.5M | -2.30M | -1.29M |
| Research and development | 69.5M | 70.3M | 73.0M | 85.1M | 104.2M | 79.9M | 44.0M | 10.5M |
| Selling, general and administrative | 20.7M | 22.8M | 30.6M | 26.4M | 28.5M | 17.9M | 10.0M | 3.21M |
| Operating income | -88.0M | -89.2M | -88.1M | -97.6M | -128.3M | -97.8M | -54.0M | -13.7M |
| Depreciation and amortization | 930.0K | 1.03M | 1.56M | 2.31M | 3.02M | 2.73M | 1.40M | 1.29M |
| EBITDA | -87.1M | -88.1M | -86.6M | -95.3M | -125.3M | -95.1M | -52.6M | -12.4M |
| Interest expense | 1.64M | 132.0K | 10.5M | 1.86M | 0 | |||
| Income before tax | -23.9M | -130.9M | -86.9M | -95.9M | -128.2M | -108.4M | -52.2M | -13.9M |
| Income tax | 314.0K | 331.0K | 795.0K | 106.0K | 143.0K | 161.0K | 85.0K | -272.0K |
| Net income | -24.2M | -131.2M | -87.7M | -96.0M | -128.3M | -108.5M | -52.3M | -13.9M |
| Earnings per share, basic | -2.45 | -20.94 | -34.20 | -2.25 | -3.22 | -10.87 | -26.04 | -0.66 |
| Earnings per share, diluted | -2.45 | -20.94 | -34.20 | -2.25 | -3.22 | -10.87 | -26.04 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 18.3M | 37.0M | 135.7M | 81.3M | 186.8M | 220.4M | 69.6M | 24.0M |
| Short-term investments | 59.5M | 19.9M | -70.0K | 44.5M | 3.92M | 23.1M | 48.1M | 66.8M |
| Current assets | 82.9M | 62.1M | 141.1M | 133.5M | 204.4M | 250.0M | 120.2M | 92.4M |
| Property, plant and equipment | 1.87M | 2.36M | 3.26M | 4.82M | 6.18M | 8.01M | 8.52M | 15.2M |
| Total assets | 88.5M | 70.1M | 151.5M | 146.7M | 235.4M | 265.3M | 146.5M | 107.7M |
| Accounts payable | 3.98M | 2.57M | 2.52M | 4.74M | 3.02M | 3.31M | 3.77M | 2.98M |
| Current liabilities | 21.2M | 21.7M | 23.9M | 33.1M | 39.0M | 30.3M | 13.8M | 7.49M |
| Total debt | 5.25M | 8.38M | 11.1M | 12.6M | 14.5M | 13.0M | 14.3M | 13.9M |
| Total liabilities | 35.0M | 99.1M | 59.4M | 42.8M | 50.6M | 45.3M | 29.3M | 121.5M |
| Shareholders' equity | 53.5M | -29.0M | 92.1M | 103.9M | 184.7M | 220.0M | -64.9M | -13.7M |
| Shares outstanding | 6.18M | 3.86M | 3.00M | 42.9M | 42.7M | 38.1M | 3.93M | 21.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -82.5M | -80.7M | -79.0M | -79.4M | -115.7M | -74.3M | -46.8M | -6.05M |
| Capital spending | -437.0K | -130.0K | -19.0K | -943.0K | -892.0K | -2.06M | -2.79M | -2.52M |
| Free cash flow | -82.9M | -80.9M | -79.0M | -80.3M | -116.6M | -76.3M | -49.6M | -8.56M |
| Cash from investing | -37.8M | -18.3M | 45.0M | -26.3M | 3.02M | 32.8M | 6.79M | -69.3M |
| Cash from financing | 101.6M | 355.0K | 88.3M | 164.0K | 78.7M | 192.3M | 85.5M | 99.9M |
| Share buybacks | 225.0K | 79.6M | 156.9M | |||||
| Change in cash | -18.7M | -98.7M | 54.3M | -105.5M | -34.0M | 150.8M | 45.6M | 24.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2026 | Results | SEC |
| 8-K · Current report | Sep 15, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2026 | Management or board change | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 24, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 21, 2026 | Material contract | SEC |
| 8-K · Current report | Apr 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Feb 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 4, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 3, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 1, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 1, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 27, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 12, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 10, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 10, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| D | Feb 28, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2025 | Material contract | SEC |
| 8-K · Current report | Feb 3, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Nov 19, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Nov 14, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 13, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 6, 2024 | Offer document | SEC |
| S-3 · Registration statement | Nov 6, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 26, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Sep 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 5, 2024 | Current report | SEC |
| 8-K · Current report | Aug 19, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 9, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 8, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 28, 2024 | Management or board change | SEC |
| 8-K · Current report | May 31, 2024 | Current report | SEC |
| 8-K · Current report | May 22, 2024 | Management or board change | SEC |
| 8-K · Current report | May 15, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 28, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 28, 2024 | Management or board change | SEC |
| SC TO-I/A | Feb 28, 2024 | Acquisition or disposal | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 8, 2024 | Big-stake notice | SEC |
| SC TO-I | Jan 30, 2024 | Acquisition or disposal | SEC |
| SC TO-C | Jan 25, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 25, 2024 | Current report | SEC |
| 424B3 · Prospectus | Nov 28, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 28, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 22, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 22, 2023 | Management or board change | SEC |
| UPLOAD · Letter from the SEC | Nov 21, 2023 | Other filings | SEC |
| S-3 · Registration statement | Nov 17, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 15, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Nov 7, 2023 | Insider trade | SEC |
| D | Nov 7, 2023 | Other filings | SEC |
| SC 13D · Big-stake notice | Nov 6, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 2, 2023 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 2, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 2, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 25, 2023 | Material contract | SEC |
| 8-K · Current report | Oct 18, 2023 | Current report | SEC |
| 4 · Change in ownership | Sep 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 7, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 3, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Results | SEC |
| 8-K · Current report | Aug 1, 2023 | Current report | SEC |
| 8-K · Current report | Jul 25, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
| DEFR14A | Jun 2, 2023 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 4, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 4, 2023 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 9, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 9, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2023 | Results | SEC |
This page holds 200 of 350 filings. Open Filings
Cap table
Built by 6ix from Aligos Therapeutics, Inc.’s releases · as of Feb 12, 2025
- Common shares
- 5,444,558
- Fully diluted
- 5,444,558
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 5,444,558 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 5,444,558 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Heather Preston Other companies: Oxford Nanopore Technologies PLC (Non Executive Director · Since at least May 1, 2026); Akouos Inc (Director · Jun 25, 2020 – Nov 30, 2022 · Past); Fusion Pharmaceuticals Inc (Director · Jun 25, 2020 – Jun 14, 2023 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Jun 24, 2021 · Past); Entasis Therapeutics Holdings Inc (Director · Sep 25, 2018 – Jun 19, 2019 · Past); Albireo Pharma Inc (Director · Nov 3, 2016 – Jan 23, 2017 · Past); Otonomy Inc (Director · Aug 12, 2014 – Jun 11, 2019 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 22, 2019 · Past) | Director · Since at least Aug 7, 2024 |
| Bridget Martell Other companies: Delcath Systems, Inc. (Director · Since at least May 23, 2024); Achieve Life Sciences, Inc. (Director · Since at least Mar 15, 2021); Ayala Pharmaceuticals Inc (Director · Oct 18, 2023 – Oct 18, 2023 · Past); POINT Biopharma Global Inc (Director · Jun 12, 2023 – Jun 13, 2023 · Past); Kura Oncology, Inc. (Acting Chief Medical Officer · Feb 10, 2020 – Aug 24, 2020 · Past) | Director · Since at least Nov 16, 2021 |
| Jack Nielsen Other companies: ALX Oncology Holdings Inc. (Director · Jun 15, 2022 – Jun 20, 2023 · Past); Instil Bio, Inc. (Director · May 20, 2022 – Jun 14, 2023 · Past); Harmony Biosciences Holdings, Inc. (Director · Mar 30, 2022 – May 29, 2024 · Past) | Director · Jun 23, 2022 – Feb 27, 2024 · Past |
| Kathleen Sereda Glaub Other companies: Codexis, Inc. (Director · Jun 11, 2019 – Jun 11, 2019 · Past) | Director · Oct 15, 2020 – Oct 15, 2020 · Past |
| K. Peter Hirth Other companies: Vaxcyte, Inc. (Director · Jun 11, 2020 – Jun 6, 2024 · Past) | Director · Since at least Oct 15, 2020 |
| Carole Nuechterlein | Director · Since at least Nov 5, 2026 |
| David B. Smith | Executive Vice President, Head of Chemical Operations · Since at least Dec 11, 2025 |
| James Scopa | Director · Since at least Nov 5, 2026 |
| Jim Hassard | EVP, Chief Commercial Officer · Since at least Jan 13, 2026 |
| Jordyn Tarazi | Vice President, Investor Relations & Corporate Communications · Since at least Oct 5, 2026 |
All 20 people
| Person | Seat |
|---|---|
| Julian Symons | Executive Vice President, Chief Scientific Officer · Since at least Oct 15, 2020 |
| Kristina Engeseth | Senior Vice President, Head of People & Culture · Since at least Nov 4, 2026 |
| Lawrence M. Blatt | President and CEO, Director · Since at least Jul 16, 2025 |
| Lesley Ann Calhoun | Executive Vice President, Chief Operating Officer, and Chief Financial Officer · Since at least May 20, 2025 |
| Lucinda Y Quan | See Remarks · Oct 15, 2020 – Sep 8, 2023 · Past |
| Margarita Chavez | Director · Since at least Aug 7, 2024 |
| Matthew W McClure | Chief Medical Officer · Apr 27, 2022 – Mar 1, 2024 · Past |
| Rámon Polo | Senior Vice President, Head of Global Regulatory Affairs · Since at least Aug 20, 2025 |
| Sushmita M. Chanda | Executive Vice President, Chief Development Officer · Since at least Aug 20, 2025 |
| Tse-I Lin | Senior Vice President, Early Compound Development, Belgian Site Head · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Aligos Therapeutics, Inc.